PCSK9 and familial hypercholesterolemia: As an example, the D374Y PCSK9 mutation associated with severe hypercholesterolemia was found to greatly increase PCSK9-LDLR binding affinity and cellular LDLR degradation via an extracellular pathway, validating early in vitro evidence of the PCSK9-LDLR interaction (2).